C. Veyrat-Follet

发表

Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer

France Mentré, Solène Desmée, Christine Veyrat-Follet, 2017, BMC Medical Research Methodology.

Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients

J. Guedj, F. Mentré, S. Desmée, 2017, Biometrics.

Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors

F. Mentré, C. Veyrat‐Follet, E. Comets, 2013, Cancer Chemotherapy and Pharmacology.

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

Y. Shitara, C. Veyrat‐Follet, Hoai‐Thu Thai, 2023, CPT: pharmacometrics & systems pharmacology.

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

C. Veyrat‐Follet, Hoai‐Thu Thai, D. Sémiond, 2021, British journal of clinical pharmacology.

Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization

C. Veyrat‐Follet, R. Bruno, R. Olivares, 2000, Clinical pharmacology and therapeutics.

Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

C. Veyrat‐Follet, Florent Mazuir, Hoai‐Thu Thai, 2015, British journal of clinical pharmacology.

Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

René Bruno, Gerald R. Rhodes, Christine Veyrat-Follet, 2001, Investigational New Drugs.

Physiology of Chemotherapy-Induced Emesis and Antiemetic Therapy

R. Farinotti, C. Veyrat‐Follet, J. Palmer, 1997, Drugs.

A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed‐effects models

France Mentré, Emmanuelle Comets, Nicholas H G Holford, 2013, Pharmaceutical statistics.

The pharmacokinetics of idraparinux, a long‐acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials

C. Veyrat‐Follet, G. Sanderink, N. Vivier, 2009, Journal of thrombosis and haemostasis : JTH.

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

L. Nguyen, C. Veyrat‐Follet, Hoai‐Thu Thai, 2022, CPT: pharmacometrics & systems pharmacology.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

V. Diéras, A. van der Gaast, H. Fontaine, 2014, British Journal of Cancer.

Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

V. Diéras, H. Fontaine, D. Tosi, 2010 .

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

L. Nguyen, C. Veyrat‐Follet, Hoai‐Thu Thai, 2021, CPT: pharmacometrics & systems pharmacology.

A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.

F. Mentré, C. Veyrat‐Follet, E. Comets, 2011, British journal of clinical pharmacology.

A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron

Lewis B. Sheiner, Stuart L. Beal, L. Sheiner, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials

S. Cartot-Cotton, Laure Deyme, M. Cerou, 2024, CPT: pharmacometrics & systems pharmacology.